C83.32 ICD-10-CM Code: Diffuse large B-cell lymphoma, intrathoracic lymph nodes
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C83.32
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceDiffuse large B-cell lymphoma, intrathoracic lymph nodes
A type of aggressive blood cancer (diffuse large B-cell lymphoma) affecting lymph nodes inside the chest cavity.

Buddy Insight
Diffuse large B-cell lymphoma of intrathoracic lymph nodes may present as mediastinal mass on chest imaging, sometimes causing superior vena cava syndrome, cough, or dyspnea.
CMS-HCC V28
MappedHCC 20
RAF 1.136
CMS-HCC V24
MappedHCC 10
RAF 0.675
ACA/HHS
MappedHCC 10
Varies by metal level
ESRD/PACE
MappedHCC 10
RAF 0.111
RXHCC
MappedHCC 21
RAF 0.410
Code Book Path
Inclusion Terms
Official- Anaplastic diffuse large B-cell lymphoma
- CD30-positive diffuse large B-cell lymphoma
- Centroblastic diffuse large B-cell lymphoma
- Diffuse large B-cell lymphoma, subtype not specified
- Immunoblastic diffuse large B-cell lymphoma
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C83.32 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C83.32 in this effective period.
Excludes 1
Official- mediastinal (thymic) large B-cell lymphoma (C85.2-)
- mature T/NK-cell lymphomas (C84.-)
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C83.32 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C83.32 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C83.32 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.
Is C83.32 an HCC code?
Yes. C83.32 (Diffuse large B-cell lymphoma, intrathoracic lymph nodes) maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lymphoma and Other Cancers under V24), with a community non-dual aged RAF of 1.136. It is billable for payment year 2026.
Coder answer: C83.32 is billable and maps to V28 HCC 20, Lung and Other Severe Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- C83.32
- Description
- Diffuse large B-cell lymphoma, intrathoracic lymph nodes
- HCC (V28)
- HCC 20 — Lung and Other Severe Cancers
- RAF
- 1.136
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
Work C83.32 in the Code Book — tabular path, V28 RAF, and MEAT checklist →
MEAT Criteria for C83.32
For C83.32to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C83.32 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 RAF + MEAT cheat sheet
One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
C83.32 is the ICD-10-CM diagnosis code for diffuse large b-cell lymphoma, intrathoracic lymph nodes. A type of aggressive blood cancer (diffuse large B-cell lymphoma) affecting lymph nodes inside the chest cavity. C83.32 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C83.32 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 1.136. Under the older CMS-HCC V24 model, C83.32 maps to Lymphoma and Other Cancers (HCC 10) with a community, non-dual, aged base RAF weight of 0.675. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Intrathoracic lymph nodes include mediastinal and hilar nodes; ensure documentation specifies this location. Because C83.32 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C83.32 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Intrathoracic lymph nodes include mediastinal and hilar nodes; ensure documentation specifies this location
- •Cross-reference imaging reports (CT chest) to confirm lymph node involvement in the thorax
Clinical Significance
Diffuse large B-cell lymphoma of intrathoracic lymph nodes may present as mediastinal mass on chest imaging, sometimes causing superior vena cava syndrome, cough, or dyspnea. Primary mediastinal large B-cell lymphoma is a distinct subtype coded differently (C85.2-), so pathological distinction is critical.
Documentation Requirements
- ✓Pathology with immunohistochemistry confirming DLBCL (not primary mediastinal large B-cell lymphoma)
- ✓CT chest or PET/CT documenting intrathoracic lymph node involvement
- ✓Specific thoracic node groups identified (mediastinal, hilar, paratracheal)
- ✓Assessment for airway compression or vascular compromise
- ✓Differentiation from primary mediastinal large B-cell lymphoma (CD23, CD30, MAL markers)
Commonly Confused Codes
- •C85.22: Mediastinal (thymic) large B-cell lymphoma, intrathoracic; distinct entity from DLBCL with different immunophenotype
- •C83.12: Mantle cell lymphoma, intrathoracic; different subtype
- •C83.52: Lymphoblastic lymphoma, intrathoracic; different biology and treatment
- •C34.-: Malignant neoplasm of bronchus/lung; solid organ lung lesion, not lymph node disease

